Abstract
Recommended first-line treatment:
– Artemisinin-based combination therapy (ACT)
– Adopted by WHO in 2005
– Resistance to non-artemisinin therapy (e.g. SP)
– Bans on oral artemisinin monotherapies
Large treatment gap persists
– Children with confirmed malaria who receive ACT ranges from 1% to 42%